Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Bio-Techne's Revenue for the
three
months ended in Dec. 2023 was $273 Mil. Bio-Techne's Total Assets for the quarter that ended in Dec. 2023 was $2,743 Mil. Therefore, Bio-Techne's Asset Turnover for the quarter that ended in Dec. 2023 was 0.10.
Asset Turnover is linked to ROE % through Du Pont Formula. Bio-Techne's annualizedROE % for the quarter that ended in Dec. 2023 was 5.55%. It is also linked to ROA % through Du Pont Formula. Bio-Techne's annualizedROA % for the quarter that ended in Dec. 2023 was 4.01%.
Bio-Techne Asset Turnover Historical Data
The historical data trend for Bio-Techne's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bio-Techne's Asset Turnover
For the Biotechnology subindustry, Bio-Techne's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne's Asset Turnover Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Bio-Techne's Asset Turnover falls into.
Bio-Techne Asset Turnover Calculation
Asset Turnover measures how quickly a company turns over its asset through sales.
Bio-Techne's Asset Turnover for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Bio-Techne (NAS:TECH) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
Bio-Techne's annulizedROE % for the quarter that ended in Dec. 2023 is
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Bio-Techne's annulizedROA % for the quarter that ended in Dec. 2023 is
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Bio-Techne Asset Turnover Related Terms
Thank you for viewing the detailed overview of Bio-Techne's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TECH has been successfully added to your 